2020-10-27 16:00Financial Performance - Net profit attributable to shareholders was CNY 112,646,895.39, down 55.13% year-on-year[5] - Operating revenue for the first nine months was CNY 892,155,592.36, representing a decline of 22.06% compared to the same period last year[5] - Basic earnings per share were CNY 0.63, down 59.87% from the previous year[6] - The company reported a total revenue of RMB 892.16 million for the current period, a decrease of RMB 252.55 million or 22.06% compared to the same period last year[16] - The main business revenue was RMB 891.25 million, down RMB 251.71 million or 22.02% year-on-year[16] - The ophthalmology product line generated revenue of RMB 381.80 million, accounting for 42.84% of total revenue, a decrease of 23.88% from the previous year[16] - The orthopedic product line revenue was RMB 224.61 million, representing 25.20% of total revenue, down 11.12% year-on-year[16] - The company reported a total operating cost of ¥317,248,919.13 for Q3 2020, compared to ¥299,886,373.78 in Q3 2019, indicating an increase of approximately 5.5%[27] - The company reported a total comprehensive income of ¥21,558,659.11 for Q3 2020, compared to ¥9,375,995.01 in Q3 2019, indicating an increase of approximately 130%[30] Cash Flow and Investments - The net cash flow from operating activities was CNY 110,051,983.31, a decrease of 45.17% year-on-year[5] - The company reported a net cash outflow from investing activities of CNY -381,425,700.69, primarily due to new investment agreements[20] - The company’s total cash outflow from operating activities was 308,036,938.41 RMB, slightly lower than 310,538,577.16 RMB in the same period of 2019[33] - The company reported a significant decrease in cash received from other operating activities, totaling 12,128,171.10 RMB, down from 25,591,020.00 RMB in the same period of 2019[33] - The company experienced a net cash outflow from investment activities of -53,687,241.10 RMB, compared to a positive cash flow of 68,443,479.99 RMB in the prior year[34] - Cash and cash equivalents at the end of the period stood at 303,326,921.67 RMB, down from 46,332,226.90 RMB in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,145,082,708.57, a decrease of 0.11% compared to the end of the previous year[5] - The total liabilities increased to CNY 558,874,882.17 from CNY 498,516,864.48 at the end of 2019[23] - The company reported a decrease in accounts receivable to CNY 316,448,358.65 from CNY 381,990,938.69 year-on-year[22] - The company’s total liabilities as of September 30, 2020, were ¥320,395,320.67, compared to ¥177,729,022.12 in the previous year, showing a significant increase[26] - The total equity attributable to shareholders decreased to ¥4,152,760,978.36 from ¥4,287,888,951.10 at the end of 2019[26] Research and Development - Research and development expenses accounted for 9.43% of operating revenue, an increase of 2.49 percentage points compared to the previous year[6] - Research and development expenses for Q3 2020 were ¥27,529,488.77, slightly down from ¥28,105,188.21 in Q3 2019[27] - Research and development expenses for Q3 2020 were ¥8,615,954.67, a decrease from ¥11,799,584.47 in Q3 2019, representing a reduction of about 27%[29] Market and Product Development - The company anticipates a recovery in domestic business, with major product lines showing positive growth trends in the third quarter[17] - The company plans to continue expanding its product offerings and market presence through strategic initiatives and product differentiation[18] - The launch of the third-generation hyaluronic acid product "Hai Mei" occurred on August 7, 2020, aimed at consolidating the company's leadership in the domestic hyaluronic acid market[18] - The company successfully participated in bulk procurement for high-value medical consumables in various provinces, enhancing market share for its intraocular lens products[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,567[8]